| P50 | author | Masafumi Ikeda | Q88949904 |
| | Junji Furuse | Q89869443 |
| | Akiyoshi Kasuga | Q48621687 |
| P2093 | author name string | Hideaki Takahashi | |
| | Takuji Okusaka | |
| | Tatsuya Ioka | |
| | Daniel J Felitsky | |
| | Chigusa Morizane | |
| | Fanghong Zhang | |
| | Caretha L Creasy | |
| | Akiko Todaka | |
| | Akira Fukutomi | |
| | Mikiro Kobayashi | |
| | Shelby Gorman | |
| P2860 | cites work | Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study | Q57422108 |
| | Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness | Q83969569 |
| | Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence | Q27852894 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. | Q30241563 |
| | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles | Q32173000 |
| | Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. | Q33390549 |
| | Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | Q33390747 |
| | The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma | Q33441341 |
| | Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas | Q33581027 |
| | Genes and viruses in hepatobiliary neoplasia | Q34110995 |
| | Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition | Q34221658 |
| | Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 |
| | Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers | Q35023456 |
| | Biliary tract cancers: SEOM clinical guidelines | Q36400234 |
| | A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer | Q36795363 |
| | Targeted therapy for biliary tract cancer | Q37132750 |
| | Systemic therapy for biliary tract cancers | Q37151623 |
| | Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. | Q37588461 |
| | Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss | Q37623870 |
| | Second-line therapy in advanced biliary tract cancer: what should be the standard? | Q38115859 |
| | Second-line chemotherapy in advanced biliary cancer: a systematic review | Q38207456 |
| | MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade | Q38788877 |
| | GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition | Q39606314 |
| | KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients | Q39820471 |
| | Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. | Q40860251 |
| | Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma | Q43005729 |
| | Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). | Q44488107 |
| | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers | Q46107145 |
| | S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study | Q46795508 |
| | Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. | Q47280618 |
| | Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. | Q52764639 |
| | Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. | Q53268257 |
| | Genomic spectra of biliary tract cancer. | Q53390123 |
| | Mutational landscape of intrahepatic cholangiocarcinoma. | Q54300991 |
| P433 | issue | 1 | |
| P304 | page(s) | 215-224 | |
| P577 | publication date | 2017-12-09 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine | |
| P478 | volume | 109 | |